Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (NCT03375320)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Documentation of Disease:
2. Histologic Documentation: Well- or moderately-differentiated neuroendocrine tumors of pancreatic and non-pancreatic (i.e. carcinoid) origin by local pathology
3. The pathology report must state ONE of the following: 1) well- or moderately-differentiated neuroendocrine tumor, 2) low- or intermediate-grade neuroendocrine tumor, or 3) carcinoid tumor or atypical carcinoid tumor; documentation of histology from a primary or metastatic site is allowed
4. Patients with poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma without specification of differentiation status, adenocarcinoid tumor, or goblet cell carcinoid tumor are not eligible. Patients with well-differentiated grade 3 neuroendocrine tumor are eligible
5. Stage: Locally advanced/unresectable or metastatic disease
6. Tumor Site: Histological documentation of neuroendocrine tumor of pancreatic, gastrointestinal (GI), lung, thymus, other, or unknown primary site; GI, lung, thymus, other, and unknown primary NETs will enroll in the carcinoid tumor cohort of the study
7. Functional (i.e., associated with symptoms or clinical syndrome related to hormone secretion by tumor) or nonfunctional tumors are allowed
8. Radiologic Evaluation: Target lesions must have shown evidence of disease progression by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria in the 12 months prior to registration; the radiologic images, imaging reports, and clinic notes indicating growth of existing lesions, development of new lesions, or treatment changes must be submitted
9. Measurable Disease
10. Patients must have measurable disease per RECIST 1.1 by computer tomography (CT) scan or magnetic resonance imaging (MRI)
11. Lesions must be accurately measured in at least one dimension (longest diameter to be recorded) as \>= 1 cm with CT or MRI (or \>= 1.5 cm for lymph nodes); non-measurable disease includes disease smaller than these dimensions or lesions considered truly non-measurable including: leptomeningeal disease, ascites, pleural or pericardial effusion, lymphangitic involvement of skin or lung
12. Prior Treatment

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (432 Sites)

• Katmai Oncology Group — Anchorage, Alaska
• Kingman Regional Medical Center — Kingman, Arizona
• Mayo Clinic Hospital in Arizona — Phoenix, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• Kaiser Permanente-Deer Valley Medical Center — Antioch, California
• PCR Oncology — Arroyo Grande, California
• Sutter Auburn Faith Hospital — Auburn, California
• Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
• Mills-Peninsula Medical Center — Burlingame, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• Epic Care-Dublin — Dublin, California
• Epic Care Partners in Cancer Care — Emeryville, California
• Kaiser Permanente-Fremont — Fremont, California
• Palo Alto Medical Foundation-Fremont — Fremont, California
• Kaiser Permanente-Fresno — Fresno, California
• Contra Costa Regional Medical Center — Martinez, California
• Fremont - Rideout Cancer Center — Marysville, California
• Memorial Medical Center — Modesto, California
• Kaiser Permanente-Modesto — Modesto, California
• Palo Alto Medical Foundation-Camino Division — Mountain View, California
• Alta Bates Summit Medical Center - Summit Campus — Oakland, California
• Kaiser Permanente-Oakland — Oakland, California
• Palo Alto Medical Foundation Health Care — Palo Alto, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.